Abstract
Purpose: To study the effects of butylphthalide in patients with vascular cognitive impairment. 
 Method: Sixty patients with vascular cognitive impairment were randomly divided into control group and butylphthalide (NBP) group (n = 30). Control group received blood pressure control, blood sugar control, and lipid-lowering therapies, while NBP group received butylphthalide capsules (200 mg, thrice daily). Treatments in both groups lasted for 14 days. Thereafter, Hasegawa Dementia Scale (HDS), Mini-Mental State Examination (MMSE), Activities of Daily Living Scale (ADL), and event-related potential (P300) were used to evaluate the effects of butylphthalide treatment. 
 Result: Following 14 days of treatment, HDS, MMSE and ADL scores of NBP group were significantly higher than those of the control group (p < 0.05). The P300 latency of NBP group was shorter than that of control group, while P300 amplitude was higher than that of control group (p < 0.05). 
 Conclusion: Butylphthalide treatment achieves higher scores of HDS, MMSE and ADL scores, but shorter P300 latency. These results provided good evidence of the effectiveness of butylphthalide therapy in the management of vascular cognitive impairment. However, further clinical trials are recommended prior to application in clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have